atogepant
New Research Shows Atogepant Works Quickly to Prevent Migraines
New research suggests that atogepant, a calcitonin gene−related peptide receptor antagonist, may work ...
JANUARY 10, 2025
FDA Approves Atogepant to Prevent Chronic Migraine in Adults
Atogepant becomes the first oral CRGP receptor antagonist approved to prevent both episodic and chronic ...
APRIL 19, 2023
FDA Approves First Oral CGRP Receptor Antagonist Specifically Developed for Migraine Prevention
The FDA approved atogepant for the preventive treatment of episodic migraine in adults.
SEPTEMBER 30, 2021
Load more